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Cell kinetics was determined, as 3H-thymidine labeling index (LI), in hepatic lesions from 36 patients with
primary colorectal carcinoma; LI values ranged from 0.9% to 23.5% and were normally distributed. Cell
kinetics was not related to sex or age of the patient, or to liver function. For clinical studies the median LI
value of 10% was used to separate slowly and rapidly proliferating lesions. Univariate analysis showed that
patients radically resected and with a low LI tumor have a longer disease-free interval and a better probability
of 12-month survival than those non-radically resected and with a high LI tumor. When treatment and cell
kinetics were taken into consideration, the probability of 12-month survival was 100% for patients with
slowly proliferating and radically resected hepatic metastases. Patients with rapidly proliferating tumors,
regardless of type of treatment, had the worst prognosis.
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INTRODUCTION
Hepatic metastases in patients with colorectal carcinoma always represent a poor
prognostic factor for patient survival. However, the clinical course varies from a few
months to some years.
Various classifications have been proposed 1-8, and biologic markers and pathologic
features indicative of risk have been analyzed in multivariate analyses and ranked
9 10,11 according to their relative ability to predict survival
Cell kinetics, a variable ofprognostic relevance already proved in somehuman tumor
12-18 types, has been determined in primary colorectal tumors but it has never been
investigated in hepatic metastases. With the present study, we proposed to define the
potential proliferative activity of hepatic metastases from colorectal carcinoma, in the
different clinico-pathologic situations, and to investigate its prognostic relevance and
its relative importance compared with conventional factors in predicting clinical out-
come.
*Address reprint requests to: Rosella Silvestrini, Ph.D.,- Istituto Nazionale Tumori, Via Venezian 1,20133
Milan, Italy.
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PATIENTS AND METHODS
From November 1984 to September 1986, 36 patients with hepatic metastases from
colorectal adenocarcinoma underwent laparotomy to perform liver resection or posi-
tioning of an intraarterial catheter for intrahepatic chemotherapy at the Istituto
Nazionale Tumori of Milan. There were 15 females and 21 males, whose ages ranged,
at the time of liver resection, from 28 to 70 years (mean, 53 years). In 17 patients the
primary was in the colon, in 12 patients in the sigmoid, and in 7 patients in the rectum.
Fifteen were synchronous lesions and 21 were metachronous to resection ofthe primary
colorectal tumor.
All patients were evaluated by echotomography, computerized axial tomography
(CT), and angiography ofthe arterial and venous systems ofthe liver. The patients were
staged according to the classification proposed by Gennari et aL l" the extent of liver
replacement was defined as HI, involvement less than 25%; H2, from 25% to 50%; and
H3, more than 50%. Biochemical determinations of alkaline phosphatase (AP) and
carcinoembryonic antigen (CEA) serum levels were performed at the time ofdiagnosis.
Twelve patients underwent radical resection ofhepatic metastases. In 24 the bilateral
extent of metastatic disease in the liver or the presence ofextrahepatic intraabdominal
growth did not allow surgical treatment. Three of them had debulking surgery plus
intraperitoneal administration of 5- fluorouracil. In 11 an intraarterial infusion device
was implanted to allow continuous infusion chemotherapy with floxuridine. In the
others systemic chemotherapy with 5-fluorouracil was given.
Follow-up studies included CEA assay, liver function tests, echotomography and/or
CT every 2-3 months. In the absence of suspected local progression of the disease, a
chest roentgenogram was performed at 4-6 month intervals.
Cell kinetics was determined on fresh tumor material immediately after surgery.
Tumor tissue, after removal of necrotic areas, was minced into fragments of a few
millimeters: 5-10 fragments were incubated in McCoy’s 5Amedium modified with20%
fetal calf serum, antiobiotics (100 IU of penicillin and 100g of streptomycin/ml) and 6
mCi/ml of 3H- thymidine (s.a., 5 Ci/mmol) for h in a Dubnoff shaker bath at 37C.
After incubation, the samples were fixed in Bouin’s solution, dehydrated in alcohol and
embedded in paraffin. Autoradiography was performed on histologic sections accord-
ing to the stripping film (Kodak AR10, London, U.K.) technique. After an exposure
time of 10 days at 4"C, autoradiograms were developed in Kodak Dl9b for 5 min at
18"C and fixed in Kodak F5. The samples were stained with hematoxylin and eosin at
4"C 19. Proliferative activity was determined bs{ scoring a total of 3,000 to 10,000 tumor
cells for each tumor and was expressed as H-thymidine labeling index (LI). The
median LI value of 10%, defined for the overall series, was used as the cutoff point to
define slowly and rapidly proliferating tumors.
Nonparametric statistics, Wilcoxon and Kruskall-Wallis tests were used to compare
the cell kinetic pattern of different subtypes. All hypothesis tests were two sided.
Freedom from progression (FFP) was considered as the interval between the start of
treatment and the first documented evidence of treatment failure. The actuarial life
table method was used to summarize FFP and overall survial distributions, and the
statistical significance of differences observed was assessed by the logrank test:. The
median time of observation for the overall series of patients was 10 months. The
percentage of progression-free or live patients was reported for one point in time (12
months) as derived from life-table plots.CELL KINETICS OF COLORECTAL HEPATIC METASTASES 137
RESULTS
LI values, recorded on the overall series, showed a normal distribution with an
interpatient variability from 0.9% to 23.5% and a median LI value of 10% (Figure 1).
Cell kinetics was not related to sex or patient’s age, and similar spectra of LI values
were observed irrespectively of the site of the primary tumor as well as for synchronous
and metachronous lesions (Table 1). Median LI values were similar in patients with
surgically resectable or non-resectable metastases.
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Figure Frequency distribution of labeling index values of hepatic metastases from colorectal adenocar-
cinoma.
Cell kinetics of hepatic lesions were not related to CEA levels determined before
hepatic resection (data not presented). Similarly, broad LI ranges and no significantly
different median values were found for patients with pretreatment low or high alkaline
phosphatase levels by using as a cutoff value 279 IU, according to Szasz test (9.3% vs
11.6%) (Figure 2). Conversely, an overall trend of a direct relation, although not
statistically significant, was observed between LI values and degree of liver involve-
ment, this finding was limited to synchronous metastases (Table 2).
Various biologic, pathologic and treatment variables have been individually ana-
lyzed as predictors ofFFP and survival at 12 months for the 35 patients with available
follow-up information (Table 3). The median LI of hepatic lesions for this series of
patient was 10%, and it included 16 patients with slowly proliferating and 19 patients138 R. SILVESTRINI ET AL.
with rapidly proliferating metastases. The probabilities of FFP and survival for the
overall series were 28 and 56%, respectively, in agreement with the data reported from
clinical studies on large series of patients. Univariate analysis showed that outcome of
surgery, cell kinetics and time of diagnosis of metastases were significant indicators of
FFP, with the highest relevance tbr radical surgery. Radical resection still represented
an important discriminant of survival, even though cell kinetics appeared somewhat
superior in predicting long-term clinical outcome, whereas time of diagnosis of meta-
stases lost its relevance as an indicator of survival.
Table Cell kinetics ofhepatic metastases in relation to characteristics ofthe patients, primary tumor and
metastases
No. of Labeling index (%)
cases Median Range
Sex
Male 21 9.5 3.7-18.3
Female 15 11.2 0.9-23.5
Age (yrs)
<50 13 8.5 3.4-23.5
> 50 23 10.0 0.9-20.0
Primary Lesion
Colon 17 10.4 0.9-16.6
Sigmoid-colon 12 9.6 3.7-23.5
Recrum 7 10.9 3.4-18.3
Metastases
Synchronous 15 10.4 3.7-23.5
Metachronous 21 9.8 0.9-13.8
Table 2 Cell kinetics of hepatic metastases in relation to proposed clinical staging
No. of Median labeling index (%)
cases Overall Synchronous Metachronous
metastases metasteses
H 16 9.4 9.4 8.6
H2 12 10.4 10.4 9.3
n 8 14.1 17.1 10.8
The relative prognostic relevance of treatment and cell kinetics, as the two most
important prognostic factors for this series ofpatients, was analyzed. Bivariate analysis
showed that cell kinetics was an additional significant discriminant of survival within
a group of patients with resectable metastases (Figure 3). In fact, all patients with low
LI hepatic lesions were alive at 12 months. Conversely, only about one-third ofpatients
with high LI metastases have a probability to survive at that time. Median time to
progression (TTP) was not reached in the former subgroup, and it was 6 months in theCELL KINETICS OF COLORECTAL HEPATIC METASTASES 139
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Figure 2 Scattergrams of labeling index values in relation to levels of alkaline phosphatas
I synchronous lesions; metachronous lesions).
latter. In patients with unresectable metastases, median TTP and survival rate at 12
months for patients with low LI lesions were double those observed for patients with
high LI lesions. The difference was not statistically different (Figure 4).
The analysis of FFP and survival rates within homogeneous cell kinetic subgroups
failed to demonstrate significant differences between patients with resectable and those140 R. SILVESTRINI ETAL.
with unresectable metastases except for a trend in survival of patients with low LI
hepatic metastases (Table 4).
Table 3 Clinical outcome as a function of clinical, pathologic or biologic variables
Probability (%) at 12 mo
FFP* p Survival p
Treatment
Radical surgery 56
Nonradical surgery 7 < 0.01
Cell kinetics
Low LI 34
High LI 17 0.04
Metastases
Metachronous 37
Synchronous 7 0.02 72
36
78
43 0.05
79
22 <0.01
as
*FFP: Freedom from Progression
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Figure 3 Actuarial survival ofpatients with hepatic metastases radically resected. Broken line, low labeling
index _<. 10%); solid line, high labeling index(> 10%). The difference between the two curveswas statistically
significant (p 0.03).CELL KINETICS OF COLORECTAL HEPATIC METASTASES 141
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Figure 4 Actuarial survival of patients whose hepatic metastases were non-radicallyresected. Broken line,
lo.w labeling index (_<. 10%); solid line, high labeling index (> 10%). The difference between the two curves
was not statistically different.
Table 4 Prognostic relevance of surgical treatment in cell kinetic subgroups of patients
No. of Probability (%) at 12 mo
LI cases FFP Survival
RS* nonRS** p RS nonRS p
Low 16 58 25 ns 100 63 0.09
High 19 25 8 ns 38 32 ns
RS: radical surgery
nonRS: nonradical surgery
In conclusion, when type of surgery and cell kinetics were taken into consideration,
100% ofthe patients with slowly proliferating and radically resected hepatic metastases
had a probability of 12-month survival. Patients with rapidly proliferating tumors,
regardless oftreatment, had the worst prognosis and patients with unresectable but low
LI tumors had an intermediate prognosis.142
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During the last two decades, there has been an increasing trend to treat hepatic
metastases from colorectal cancer. In particular liver resection has become an accepted
treatment. However, the criteria for classification and staging, indications for treat-
ments and evaluation of results are still controversial. In fact, a basic uncertainty still
exists about the most relevant prognostic factors, in spite of attempts to better define
histologic, anatomic, clinical and functional parameters, which could have a real
impact on prognosisI1.
The potentials ofa biologic classification based on serum and tissue markers to give
additional or alternative information of clinical relevance have been taken into con-
sideration for some tumor types21-26.
The results ofthe present study indicate that, as observed for primary and metastatic
lesions of other tumor types27’28, cell kinetics of hepatic metastases from colorectal
carcinoma, as expressed by 3H-thymidine LI, widely varies from patient to patient.
The cell kinetic variable is largely independent ofpatient’s characteristics, sex and age,
or liver function markers ofclinical relevance, alkaline phosphatase and CEA, and only
slightly related to the degree of liver replacement in synchronous metastases.
Notwithstanding the relatively small number of patients studied and the short
follow-up, the outcome of this study is indicative of the prognostic relevance of cell
kinetics. In fact, cell kinetics is an important discriminant of FFP and even more of
overall survival. Moreover, the cell kinetic variable appears to be a further discriminant
of long-term clinical outcome in subgroups of patients defined according to one of the
most important prognostic factors, i.e. resectability of metastases.
If these findings are confirmed on a larger series of patients, cell kinetics will be used
as an important marker of risk, and its consideration, in association with the other
factors, will be mandatory for an accurate prognostic definition and a correct evalu-
ation of the actual effect of different treatments and important in planning treatment
protocols.
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INVITED COMMENTARY
Using modern diagnostic techniques and generally accepted criteria for resection, it
appears that resection ofcolorectal liver cancer will cure about 25% ofthe patients and
that the incidence of relapse is approximately 50% in both the liver and the extrahe-
patic tissues 1- 3. In patients with irresectable hepatic metastases from colorectal
cancer, palliative therapy, such as hepatic arterial infusion of fluoropyrimid-
ines, may sometimes appear to give long-term prolongation of survival. However,
no mode of palliative treatment has been shown to prolong survival in groups of
patients. Although it is a clinical impression that some patients respond favourably to144 R. ANDERSSON ET AL.
cytostatic treatment whereas others do not, it has not been possible to correlate
survival with any pre-treatmentcharacteristic other than the interval between
diagnosis and therapy4. It is clear that improved detection (staging) and better
grading of hepatic and extrahepatic disease is important for improved under-
standing and management of patients with colorectal liver cancer.
Therefore the grading method described by Silvestrini et al., is ofgreat interest. Their
finding that the LI value was a prognostic determinant in patients with resectable liver
metastases suggests that cell kinetic analysis may give prognostic information not
available by other means. The observation that the median LI values were similar in
patients with resectable and irresectable disease is potentially more important because
it does not seem to correlate with well established determinants ofprognosis in patients
with colorectal liver cancer. However, I believe that the prognostic relevance of cell
kinetic analysis is unclear because resectability (as opposed to irresectability) has been
shown to be a very strong determinant of survival in untreated patients5. At any rate,
interpretation should be cautious because the authors did not define "resectability";
for instance, it is not stated if, or to what extent, the number and localization of liver
tumours influenced the decision to resect or not. Another word ofcaution comes from
studies in patients with primary colorectal cancer in whom S phase duration and
labelling index appear unrelated to prognosis6.
It appears that the presented method has a potential for better stratification and for
better selection of treatment of patients with colorectal liver cancer. As stressed by the
authors themselves, it must be remembered, however, that the number of patients was
small and that the follow-up was short. Further studies, with other or complementary
staging systems, are necessary and will be awaited with interest, especially ifcombined
with cell kinetic analysis of the primary tumour.
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